Duchenne muscular dystrophy (DMD) is characterized in skeletal muscle by cycles of myofiber necrosis and regeneration leading to loss of muscle fibers and replacement with fibrotic connective and adipose tissue. The ongoing activation and recruitment of muscle satellite cells for myofiber regeneration results in loss of regenerative capacity in part due to proliferative senescence. We explored a method whereby new myoblasts could be generated in dystrophic muscles by transplantation of primary fibroblasts engineered to express a micro-dystrophin/eGFP (µDys/eGFP) fusion gene together with a tamoxifen-inducible form of the myogenic regulator MyoD [MyoD-ER(T)]. Fibroblasts isolated from mdx 4cv mice, a mouse model for DMD, were efficiently transduced with lentiviral vectors expressing µDys/eGFP and MyoD-ER(T) and underwent myogenic conversion when exposed to tamoxifen. These cells could also be induced to differentiate into µDys/eGFP-expressing myocytes and myotubes. Transplantation of transduced mdx 4cv fibroblasts into mdx 4cv muscles enabled tamoxifen-dependent regeneration of myofibers that express micro-dystrophin. This lineage control method therefore allows replenishment of myogenic stem cells using autologous fibroblasts carrying an exogenous dystrophin gene. This strategy carries several potential advantages over conventional myoblast transplantation methods including: 1) the relative simplicity of culturing fibroblasts compared with myoblasts, 2) a readily available cell source and ease of expansion, and 3) the ability to induce MyoD gene expression in vivo via administration of a medication. Our study provides a proof of concept for a novel gene/stem cell therapy technique and opens another potential therapeutic approach for degenerative muscle disorders.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X-linked, recessive lethal genetic disorder caused by mutation of the dystrophin gene (1, 2) . DMD is the most common neuromuscular disorder affecting approximately 1 in 3,500 newborn males (3) . Affected boys are usually diagnosed between 3 to 5 years of age (4) . Early symptoms of delayed walking and gait disturbance rapidly progress to general muscle and especially proximal weakness. By age 12, most patients use a wheelchair for mobility and often develop severe scoliosis and limb contractures. While improved clinical management has extended the life expectancy of patients in recent years, most still die in their mid to late 20's from respiratory and/or cardiac failure (5) . Current treatment options for DMD patients focus primarily on relief of symptoms and prevention of complications, as there is no effective treatment (6) .
In DMD, mutation of the dystrophin gene results in little or no production of a functional dystrophin protein (1, 2, 7) .
It is postulated that dystrophin along with the dystrophin-glycoprotein complex (DGC) plays an important role in protecting muscle fibers from eccentric contraction-induced injury (8) (9) (10) . The absence of dystrophin results in membrane instability and repeated tears in the sarcolemma with calcium entry into the muscle cell (11) . The resulting cascade of events lead muscle fibers to undergo cycles of degeneration and regeneration until the repair capacity is no longer sufficient, and muscle fibers are replaced by adipose and fibrous connective tissue (12, 13) .
In various strains of mdx mice, models for DMD, viral vector mediated gene replacement via delivery of therapeutic micro-, mini-or full-length dystrophin genes has been shown to at Pennsylvania State University on http://hmg.oxfordjournals.org/ Downloaded from prevent dystrophic changes in neonatal and young adult mice (14) (15) (16) (17) (18) . Recent studies also suggest that such vectors can stop further progression of the dystrophic phenotype and bring back some strength in old mdx mice (19, 20) . Patients with DMD, even as young boys, have fibrotic changes and fatty deposition in their affected muscles suggesting that muscle repair capacity may be already overtaxed (12) . In addition, as muscle weakness progresses, patient muscles gradually lose myofibers and it becomes increasingly difficult to isolate myoblasts that retain a robust ability to proliferate when cultured in vitro (21) . Therefore, even if viral vectors were able to target the remaining muscle fibers and myogenic precursors, there may be insufficient residual regenerative capacity to bring back significant muscle mass and strength in older patients.
Strategies to treat DMD by transplantation of wild type (allogeneic) myoblasts have previously been unsuccessful, in large part due to immune responses against the donor myoblasts (22) (23) (24) (25) (26) . Genetic modification of cells with subsequent transplantation back into the target organ (ex vivo gene therapy) represents an alternative treatment option for patients with DMD.
However, this approach is hampered by the difficulty in isolating sufficient numbers of myoblasts from a patient's own muscle that can be transduced with a dystrophin gene and expanded in culture without undergoing proliferative senescence, losing myogenic capacity or losing the ability to express muscle genes following terminal differentiation in vivo (21, (27) (28) (29) .
Nonetheless, the idea of using genetically modified autologous cells as a myogenic source still holds the advantage of potentially avoiding most of the immunological problems associated with the allogeneic approach. There are indications that several different types of stem cells besides Another issue may be tied to the multipotency of a stem cell. Due to the possibility of a stem cell being able to take various developmental pathways to becoming different cell types, there is the attendant difficulty of ensuring that a stem cell ultimately differentiates into the desired cell type for therapeutic purposes.
In this study, we evaluated fibroblasts as a source of myogenic progenitors as a therapeutic potential in the treatment of muscle disorders. In 1998, Lattanzi and coworkers demonstrated the feasibility of adenoviral mediated MyoD gene delivery to cultured fibroblasts as a potential source for muscle fiber generation in vitro. These authors showed that myoblasts converted from fibroblasts with MyoD in culture are able to form muscle fibers in vivo after intra-muscular transplantation (32) . Huard and coworkers also showed that cultured myoblasts generated from MyoD transduced fibroblasts could form myofibers in vivo, but at a very low efficiency (33) . To assess its feasibility as a potential therapeutic approach in DMD, we have investigated myogenic conversion of transplanted primary mdx fibroblasts using a tamoxifen-inducible MyoD-ER(T) gene in combination with a therapeutic gene, micro-dystrophin/eGFP, under the control of the muscle specific human skeletal α-actin promoter.
We have also used a lentiviral vector to stably transduce primary mdx 4cv fibroblasts ex vivo to allow for greater expansion of cells prior to transplantation back into the mdx muscles.
Here we show that temporally inducible MyoD-ER(T) expression results in regulated myogenic conversion of cultured and transplanted primary fibroblast both in vitro and in vivo.
Fibroblasts converted into the myogenic lineage in vivo can differentiate into dystrophin-expressing myofibers. Thus, our study demonstrates proof of principle that temporally controlled in vivo myogenic conversion of transplanted fibroblasts is feasible and opens the possibility that introduction of a drug-inducible MyoD gene with a therapeutic gene could lead to not only rescue of existing muscle fibers but may also facilitate repopulation of the muscle mass in myopathies.
RESULTS

Characterization of the MyoD-ER(T) vectors
A mouse MyoD cDNA and a second modified to contain the human estrogen receptor (for 4-hydroxytamoxifen, see methods) were initially tested by plasmid transfection into 293D cells.
Western analysis of the cell lysates showed both MyoD and MyoD-ER(T) bands, at 44 kDa and 64 KDa, respectively, indicating production of the appropriate protein products. The MyoD protein loaded in lane 1 serves as a positive control (Fig. 1A) . Lentiviral vectors used in this study are illustrated in Figure 1B .
In vitro myogenic conversion of 10T1/2 fibroblasts
To confirm that lentiviral 10T1/2 cells transduced with both the lacZ and the MyoD-ER(T) vectors were also intramuscularly transplanted into the TA muscles of 2-day-old C57Bl/6 mice after 24 hrs of 4OH-tamoxifen exposure. At 14 days after cell transplantation, TA muscles were harvested, fixed, and stained with X-gal. Nuclear-targeted β-galactosidase was clearly observed in some of the muscle fibers ( Figures 2C-E) . These data showed that 10T1/2 fibroblasts transduced with Lv-CMV-MyoD-ER(T) and exposed to 4OH-tamoxifen undergo myogenic conversion and are capable of forming myofibers in vivo after transplantation into mouse muscle.
In vivo myogenic conversion of primary fibroblasts from dystrophic mdx mice
Primary cultured fibroblasts isolated from tails of mdx 4cv mice were transduced with a lentiviral vector expressing a micro-dystrophin/enhanced green fluorescent protein fusion protein (Lv-HSA-µDys/eGFP) alone or with Lv-CMV-MyoD-ER(T) (Fig. 1B) . (Table 1) .
Cultures not exposed to tamoxifen displayed no myotube formation or µDys/eGFP expression ( Fig. 3) , although a small number of MHC positive cells were observed (Table 1) . These results
show that MyoD-ER(T) was active in initiating myogenesis in the primary fibroblasts and subsequently in inducing multinucleated myotube formation, and confirm that the HSA promoter used to drive expression of µDys/eGFP retained its muscle-specificity in the context of a lentiviral vector integrated into fibroblasts.
The doubly transduced mdx 4cv primary fibroblasts as well as those transduced only with
Lv-HSA-µDys/eGFP were cultured and expanded for 1-2 weeks before transplantation into TA muscles of mdx 4cv mice. Two weeks after intra-muscular transplantation of 1.0 x 10 6 fibroblasts, during which daily intra-peritoneal injections of 4OH-tamoxifen were performed, the TA muscles were harvested and cryosectioned. A second cohort was analyzed two weeks later.
Numerous µDys/eGFP positive fibers (160.3 +/-53.9, n=8) were found in transplants using
MyoD-ER(T) transduced cells coupled with 4OH-tamoxifen treatment, while essentially no positive fibers were detected in muscles injected with cells not expressing MyoD-ER(T) or in animals not receiving 4OH-tamoxifen ( Fig. 4A and B) . Fibroblasts from the transplantation were observed in the negative control groups. There were significant differences between transplants receiving the MyoD-ER(T) and µDys/eGFP transduced cells combined with 4OH-tamoxifen administration as compared with the other three negative control groups: no antibody ( Figures 4B and 5 ). By analyzing serial sections we found dystrophin-positive fibers spread out over an area at least 1.5 mm past the site of injection (Fig. 5B ). To identify whether the small caliber fibers represented newly generated myotubes, we looked for developmental myosin heavy chain (dMHC) expression. As shown in Figure 5A , almost all of these small, µDys/eGFP-positive fibers expressed dMHC. These studies indicate that transplanted fibroblasts expressing MyoD-ER(T) were converted to myogenic cells in vivo under the control of 4OH-tamoxifen, and subsequently followed the myogenic program by forming new myotubes and myofibers and also fusing into existing muscle fibers.
DISCUSSION
Clinical features of DMD result from the absence of a single protein, dystrophin, which ultimately leads to skeletal muscle loss and gradual replacement by fibrotic and fatty tissue.
Treatment of DMD in older patients might therefore require replenishment of myogenic progenitor cells or the muscles themselves. In this study we focused on fibroblasts as a potential source of myogenic progenitors. Studies have shown that transfection of fibroblasts with the muscle specific transcription factor MyoD causes differentiation of the fibroblasts into myoblasts (34) . In addition, it appears that the efficiency of myogenic conversion is strongly linked to the lineage relationship with muscle cells: highest in fibroblasts, lower in chondroblasts, and null in hepatocytes (35) . Other studies demonstrate that fibroblasts of different histological origins can spontaneously convert to myogenic phenotypes both in vitro and in vivo, albeit at a very low efficiency (36, 37 We have investigated the feasibility of converting fibroblasts to myogenic cells using an tamoxifen. In addition, we have chosen to utilize a retroviral method to stably transduce the fibroblasts. Previously, others have used adenoviral delivery systems (32) . However, the lentiviral system with MyoD-ER(T) may be better suited because it takes advantage of the relative ease with which fibroblasts can be expanded compared with myoblast cultures. Once the fibroblasts are stably transduced with MyoD-ER(T), they can be expanded using simplified culture conditions prior to transplantation back into the target organ. Myoblasts themselves can be difficult to expand greatly in culture and have a tendency to give rise to differentiation defective variants (28, 39) . Additionally, the use of MyoD-ER(T) prevented fibroblasts from prematurely differentiating into post-mitotic myocytes, as happens with unregulated MyoD, and therefore their proliferative capabilities are preserved. A curious result in our study was a loss in the number of dystrophin-positive myotubes between the 2 and 4 week time points, while the number of dystrophin-positive myofibers remained stable. This data could indicate that the nascent myotubes are unable to mature. It is unclear whether converted fibroblasts that fuse only with themselves or with endogenous myocytes would be able to develop normal myotendinous or neuromuscular junctions, without which maturation into normal myofibers would be blocked. This scenario is likely to be an issue for any type of myogenic stem cell transplantation, and it may be important to optimize transplant methods for fusion of myoblasts and nascent myotubes with preexisting, innervated myofibers. Alternatively, this data could mean that the small myotubes are being converted to myofibers, and that there is a slow loss of both myotubes and myofibers due to an immune response against transplanted cells, or that an immune response is directed specifically at myotubes, which, unlike myofibers, express MHC class I (40, 41) . The histological data were suggestive of an inflammatory response in transplanted muscles, although there is a certain background of immune cell infiltration in untreated mdx muscles ( Fig. 4A;(42) ).
Several aspects of the current protocol could have contributed to such an inflammatory response. The genetically modified fibroblasts used for transplantation expressed two exogenous proteins that could potentially act as foreign antigens. The first was the micro-dystrophin/eGFP fusion that was used as both a therapeutic and a marker protein.
Micro-dystrophin by itself has not elicited an immune response in previous studies, and the eGFP moiety is not essential for the strategy other than to simplify monitoring of transplanted cells (19, 20 Our studies suggest that it may be simpler to convert fibroblasts directly into a myogenic lineage for skeletal muscle engineering, although it is tempting to speculate whether a combination of these approaches might yield a progenitor cell lacking the proliferative limitations of primary fibroblasts while retaining a preference for differentiation down a myogenic pathway. Similarly, several other cell types have been studied in recent years as a source of myogenic precursors, including mesenchymal stem cells (48) , pericytes (49), mesoangioblasts (50) , and AC133+ cells (51) , and it will be important to address the potential benefits of genetically modifying these other cell types prior to transplantation.
The studies in this manuscript represent a proof of principle that fibroblasts can be used 
MATERIAL AND METHODS
Lentiviral vector constructions and preparations
The MyoD-ER(T) construction methods have been described previously (52) . Briefly, the full-length mouse MyoD cDNA was isolated and cloned from a previously described adenoviral vector (32) . A cDNA for the modified estrogen receptor responsive to tamoxifen and 4-hydroxytamoxifen, ER(T) (43) , was cloned using a PCR method with the primer pair including followed by secondary anti-rabbit IgG-Alexa594 (Molecular Probes, Eugene, OR).
Animal experiments
C57Bl/6Ros.Cg-Dmd mdx-4Cv (mdx 4cv ) and C57Bl/6 strains of mice were used. Animal experiments were approved by our Institutional Animal Care and Use Committee and were conducted in accordance with guidelines for humane treatment of laboratory animals. 10T1/2 cell harvest and centrifugation followed established protocols, and cells were resuspended in 30 MyoD-ER(T) has been described (55) . Briefly, the 4OH-tamoxifen (1 mg/100 µl suspended in 5% ethanol and 95% peanut oil) was given once a day for a total of 14 days, from 1 day prior to transplantation to day 13 post-transplantation. The animals were sacrificed at either 14 or 28 days after transplantation.
Muscle sections, immunostaining and statistical analysis
The muscles were carefully dissected and cryopreserved using Optimal Cutting Temperature compound and liquid nitrogen cooled isopentane, then muscle sections of 10 µm thickness were prepared using a cryostat. Immunostaining against dystrophin and GFP proteins were performed as previously described (18) . Briefly, the dilution ratios of the antibodies were as 
